|
|
Press Releases
All Releases
 |
ArQule, Inc. to Present at BMO Capital Markets 10th Annual Focus on Healthcare Conference
Jul 30, 2010 |
 8.5 KB |
|
| |
WOBURN, Mass., Jul 30, 2010 (BUSINESS WIRE) -- ArQule, Inc. (Nasdaq: ARQL) today announced that the Company will
present at the BMO Capital Markets 10th Annual Focus on
Healthcare Conference on August 5, 2010 at 9:30 a.m.
The presentation will be web cast live and may be accessed through the
investor relations section of th...
|
|
ArQule to Report Second Quarter 2010 Financial Results on August 4, 2010
Jul 28, 2010 |
9.0 KB |
|
| |
WOBURN, Mass., Jul 28, 2010 (BUSINESS WIRE) -- ArQule, Inc. (NASDAQ: ARQL) today announced that it will report its
financial results for the second quarter of 2010 in a press release to
be issued on Wednesday, August 4, 2010 at 7:00 a.m. eastern time. The
Company will host a conference call at 9:00 a.m. eastern time that day...
|
|
ArQule Announces Initiation by Kyowa Hakko Kirin of Phase 2 Clinical Trial in Asia with ARQ 197 in Gastric Cancer
Jul 28, 2010 |
11.4 KB |
|
| |
WOBURN, Mass., Jul 28, 2010 (BUSINESS WIRE) -- ArQule, Inc. (Nasdaq: ARQL) today announced the initiation of a Phase 2,
single agent trial with ARQ 197 in gastric cancer by Kyowa Hakko Kirin,
its exclusive licensee for the development and commercialization of ARQ
197 in the Asian territory consisting of Japan, China (includi...
|
|
ArQule, Inc. to Present at Jefferies and Needham Investment Conferences
Jun 8, 2010 |
9.0 KB |
|
| |
WOBURN, Mass., Jun 08, 2010 (BUSINESS WIRE) -- ArQule, Inc. (Nasdaq: ARQL) today announced that the Company will
present at the Jefferies 2010 Global Life Sciences Conference on June 9,
2010, beginning at 9:30 a.m. eastern time, and at the 9th
Annual Needham Healthcare Conference on June 10, 2010, beginning at
10:40 ...
|
|
ArQule and Daiichi Sankyo Present Final Phase 2 Results for ARQ 197 c-Met Inhibitor in Non-Small Cell Lung Cancer at ASCO
Jun 5, 2010 |
16.4 KB |
|
| |
WOBURN, Mass. & TOKYO, Jun 05, 2010 (BUSINESS WIRE) -- ArQule, Inc. (NASDAQ: ARQL) and Daiichi Sankyo Co., Ltd. (TSE 4568)
today announced the presentation of data from a Phase 2 clinical trial
at the 2010 Annual Meeting of the American Society of Clinical Oncology
(ASCO) showing encouraging overall survival (OS) results wit...
|
|
ArQule Provides Update on ARQ 197 Presentations at ASCO 2010
May 21, 2010 |
11.6 KB |
|
| |
WOBURN, Mass., May 21, 2010 (BUSINESS WIRE) -- ArQule, Inc. (Nasdaq: ARQL) today announced that the following
presentations of clinical data for ARQ 197, a selective inhibitor of the
c-Met receptor tyrosine kinase, will take place at the 2010 American
Society of Clinical Oncology (ASCO) Annual Meeting, which will be held
...
|
|
ArQule Reports First Quarter 2010 Financial Results
May 6, 2010 |
17.2 KB |
|
| |
WOBURN, Mass., May 06, 2010 (BUSINESS WIRE) -- ArQule, Inc. (NASDAQ: ARQL) today announced its financial results for
the first quarter of 2010.
For the quarter ended March 31, 2010, the Company reported a net loss of
$9,752,000 or $0.22 per share, compared to a net loss of $9,908,000, or
$0.23 per share, for the first quart...
|
|
ArQule to Report First Quarter 2010 Financial Results on May 6, 2010
Apr 29, 2010 |
8.9 KB |
|
| |
WOBURN, Mass., Apr 29, 2010 (BUSINESS WIRE) -- ArQule, Inc. (NASDAQ: ARQL) today announced that it will report its
financial results for the first quarter of 2010 in a press release to be
issued on Thursday, May 6, 2010 at 7:00 a.m. eastern time. The Company
will host a conference call at 9:00 a.m. eastern time that day to
...
|
|
ArQule Presentations at AACR 101St Annual Meeting Focus on Development of Oncology Pipeline
Apr 16, 2010 |
10.8 KB |
|
| |
WOBURN, Mass., Apr 16, 2010 (BUSINESS WIRE) -- ArQule, Inc. (NASDAQ: ARQL) today announced that the Company is
presenting several pre-clinical and early clinical-stage studies at the
American Association for Cancer Research (AACR) 101st Annual
Meeting, April 17-21, 2010 in Washington, D.C. that relate to the
ongoing ...
|
|
ArQule, Inc. to Present at Future Leaders in the Biotech Industry Conference
Apr 5, 2010 |
8.5 KB |
|
| |
WOBURN, Mass., Apr 05, 2010 (BUSINESS WIRE) -- ArQule, Inc. (Nasdaq: ARQL) today announced that the Company will
present at the 17th Annual Future Leaders in the Biotech
Industry conference on Thursday, April 8, 2010 at 3:00 p.m. eastern time.
The presentation will be web cast and may be accessed through the
investor relati...
|
|
ArQule Announces Results of Phase 2 Trial with ARQ 197 in Advanced Non-Small Cell Lung Cancer
Mar 31, 2010 |
15.2 KB |
|
| |
WOBURN, Mass., Mar 31, 2010 (BUSINESS WIRE) -- ArQule, Inc. (Nasdaq: ARQL) today announced that ARQ 197, when used in
combination with erlotinib, demonstrated a 66% improvement in median
Progression-Free Survival (PFS) in patients with advanced, refractory
non-small cell lung cancer (NSCLC). In the intent to treat (ITT)
...
|
|
ArQule, Inc. to Present at Cowen and Company Health Care Conference
Mar 4, 2010 |
8.4 KB |
|
| |
WOBURN, Mass., Mar 04, 2010 (BUSINESS WIRE) -- ArQule, Inc. (Nasdaq: ARQL) today announced that the Company will
present at the Cowen and Company 30th Annual Health Care
Conference on Tuesday, March 9, 2010, at 2:15 p.m. eastern time.
The presentation will be web cast live and may be accessed through the
investor relations ...
|
|
ArQule Reports Fiscal 2009 Year End and Fourth Quarter Results
Mar 2, 2010 |
20.1 KB |
|
| |
WOBURN, Mass., Mar 02, 2010 (BUSINESS WIRE) -- ArQule, Inc. (NASDAQ: ARQL) today announced its financial results for
the year and for the fourth quarter ended December 31, 2009.
The Company reported a net loss of $36,136,000, or $0.82 per share, for
the year ended December 31, 2009, compared with a net loss of
$50,864,000, ...
|
|
ArQule to Report Fiscal 2009 Financial Results on March 2, 2010
Feb 23, 2010 |
8.9 KB |
|
| |
WOBURN, Mass., Feb 23, 2010 (BUSINESS WIRE) -- ArQule, Inc. (NASDAQ: ARQL) today announced that it will report its
financial results for the fiscal 2009 year-end and fourth quarter on
Tuesday, March 2, 2010 at 7:00 a.m. eastern time. The Company will hold
a conference call at 9:00 a.m. Eastern Time that day to discuss these ...
|
|
ArQule Announces Initiation of Clinical Programs with ARQ 197 in Germ Cell Tumors and Colorectal Cancer
Feb 4, 2010 |
14.2 KB |
|
| |
WOBURN, Mass., Feb 04, 2010 (BUSINESS WIRE) -- ArQule, Inc. (Nasdaq: ARQL) today announced the initiation of a Phase 2,
single agent trial with ARQ 197 in germ cell tumors (GCT), including
testicular and non-central nervous system (non-CNS) tumors, and a Phase
1/2 clinical trial designed to evaluate the safety of ARQ 197
...
|
|
Drug Discovery Capabilities of ArQule Kinase Inhibitor Platform Presented at AACR-NCI-EORTC Conference
Nov 16, 2009 |
11.4 KB |
|
| |
WOBURN, Mass., Nov 16, 2009 (BUSINESS WIRE) -- ArQule, Inc. (Nasdaq: ARQL) today presented data at the AACR-NCI-EORTC
meeting in Boston demonstrating the capabilities of the Company's
proprietary drug discovery platform to generate a class of small
molecules with significant therapeutic potential.
These data reflect the res...
|
|
ArQule, Inc. to Present at Lazard Capital Markets Sixth Annual Healthcare Conference on November 17, 2009
Nov 10, 2009 |
8.4 KB |
|
| |
WOBURN, Mass., Nov 10, 2009 (BUSINESS WIRE) -- ArQule, Inc. (Nasdaq: ARQL) today announced that it will present at the
Lazard Capital Markets 6th Annual Healthcare Conference on
Tuesday, November 17, 2009 at 5:10 p.m. eastern time. ArQule's
presentation will be web cast live and can be accessed through the
investor r...
|
|
ArQule Announces Third Quarter Fiscal 2009 Results
Nov 5, 2009 |
21.0 KB |
|
| |
WOBURN, Mass., Nov 05, 2009 (BUSINESS WIRE) -- ArQule, Inc. (NASDAQ: ARQL) today reported its results of operations for
the fiscal quarter and nine months ended September 30, 2009.
The Company reported a net loss of $8,088,000 or $0.18 per share, for
the quarter ended September 30, 2009, compared to a net loss of
$11,281,00...
|
|
ArQule, Inc. to Report Third Quarter 2009 Financial Results on Thursday, November 5, 2009
Oct 29, 2009 |
9.0 KB |
|
| |
WOBURN, Mass., Oct 29, 2009 (BUSINESS WIRE) -- ArQule, Inc. (NASDAQ: ARQL) today announced that it will report its
financial results for the third quarter of 2009 in a press release to be
issued on Thursday, November 5, 2009 at 7:00 a.m. eastern time. The
Company will host a conference call and web cast to discuss these
...
|
|
ArQule, Inc. to Present at Oppenheimer 20th Annual Healthcare Conference on November 3, 2009
Oct 27, 2009 |
8.4 KB |
|
| |
WOBURN, Mass., Oct 27, 2009 (BUSINESS WIRE) -- ArQule, Inc. (Nasdaq: ARQL) today announced that it will present at the
Oppenheimer 20th Annual Healthcare Conference on Tuesday,
November 3, 2009 at 4:30 p.m. eastern time. ArQule's presentation will
be web cast live and can be accessed through the investor relations
se...
|
|
|
=add release to Briefcase
|
delicious
Digg
Facebook
LinkedIn
Mixx
Twitter
Yahoo! Buzz
